Page 576 - Read Online

Page 16 of 21 Toniutto et al. Hepatoma Res 2020;6:50 I http://dx.doi.org/10.20517/2394-5079.2020.40

From a clinical perspective, the search for the perfect solution between expanding the Milan criteria and
maintaining a sufficiently low risk of tumor recurrence to allow a patient survival rate of at least 60% at
5 years represents a major challenge for the coming years. The models used to predict the risk of HCC
recurrence based on the pre-transplant evaluation of all tumor characteristics (including its response to
treatments) currently represent those that combine both rigorous aspects of patient selection and organ
allocation for transplant. These two factors work synergistically to increase the benefit, effectiveness, and
justice of transplantation for HCC. The evaluation of the results obtained by adopting these criteria on large
patient series in different geographical areas will be crucial for defining their validity and applicability.

DECLARATIONS
Authors’ contributions
Wrote the paper: Toniutto P
Selected bibliography and collaborate in writing the paper: Fornasiere E, Fumolo E, Bitetto D

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018;391:1301-14.
2. Simonetti RG, Camma C, Fiorello F, Politi F, D’Amico G, et al. Hepatocellular carcinoma. A worldwide problem and the major risk
factors. Dig Dis Sci 1991;36:962-72.
3. Toniutto P, Zanetto A, Ferrarese A, Burra P. Current challenges and future directions for liver transplantation. Liver Int 2017;37:317-27.
4. Starzl TE, Marchioro TL, Vonkaulla KN, Hermann G, Brittain RS, et al. Homotransplantation of the Liver in Humans. Surg Gynecol
Obstet 1963;117:659-76.
5. Starzl TE, Groth CG, Brettschneider L, Penn I, Fulginiti VA, et al. Orthotopic homotransplantation of the human liver. Ann Surg
1968;168:392-415.
6. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, et al. Liver transplantation for the treatment of small hepatocellular
carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9.
7. Plessier A, Codes L, Consigny Y, Sommacale D, Dondero F, et al. Underestimation of the influence of satellite nodules as a risk factor for
post-transplantation recurrence in patients with small hepatocellular carcinoma. Liver Transpl 2004;10:S86-90.
8. Escartin A, Sapisochin G, Bilbao I, Vilallonga R, Bueno J, et al. Recurrence of hepatocellular carcinoma after liver transplantation.
Transplant Proc 2007;39:2308-10.
9. Valdivieso A, Bustamante J, Gastaca M, Uriarte JG, Ventoso A, et al. Management of hepatocellular carcinoma recurrence after liver
transplantation. Transplant Proc 2010;42:660-2.
10. Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller CM, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns
and prognosis. Liver Transpl 2004;10:534-40.
11. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, et al. Predicting survival after liver transplantation in patients with